Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
Explore this paper's citation graph
Summary
Treatments, which intervene as early as possible in the initiation of the pathological immune reaction and simultaneously have a favorable side-effect profile, must be the focus of future research.
- Type
- article
- Published
- 2004-01-01
- Cited by
- 7
- References
- 84
- OpenAlex
- https://openalex.org/W1548599536
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:11369732
Keywords
Immunology, Immune system, Pathogenesis, Inflammatory bowel disease, Medicine
References
- Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.
- Bioactive IL-18 expression is up-regulated in Crohn's disease.
- Proinflammatory Effects of IL-10 During Human Endotoxemia1
- The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction.
- A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses.
- Treatment of T Cell-Dependent Experimental Colitis in SCID Mice by Local Administration of an Adenovirus Expressing IL-18 Antisense mRNA1
- IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells.
- Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease.
- Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease.
- Control of immune pathology by regulatory T cells.
- Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease
- Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice.
- Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
- Interleukin 12 and Th1 responses in inflammatory bowel disease
- Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
- Four‐week open‐label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis
- Suppression of the clinical and cytokine response to endotoxin by RWJ‐67657, a p38 mitogen‐activated protein‐kinase inhibitor, in healthy human volunteers
- Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
- Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
- Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
Cited by
- Immunisation in children and adolescents with inflammatory bowel disease.
- [Socioeconomic and nutritional profile of patients with inflammatory bowel disease at a university hospital].
- Stimulatory and costimulatory effects of IL‐18 directed to different small intestinal CD43 T cell subsets
- A computational framework for the topological analysis and targeted disruption of signal transduction networks.
- IL-18 in autoimmunity: review.
- Molecular and physiological studies on the functionality of probiotic lactobacilli
- Electronic Quantitative – Structure Activity Relationships on Lipoxygenase Inhibitors #
Related papers
- The Immunopathogenesis of Ulcerative Colitis
- The advance in studies of the pathogenesis of inflammatory bowel disease
- Immune aspects of the pathogenesis of inflammatory bowel disease.
- Etiology and pathogenesis of inflammatory bowel disease.
- Immunological pathogenesis of inflammatory bowel disease
- Role of regulatory T cell in the pathogenesis of inflammatory bowel disease.
- Overview of Inflammatory Bowel Disease Pathogenesis
- Pathogenesis of inflammatory bowel disease: transcription factors in the spotlight